Следене
Evgeny Kulesskiy
Evgeny Kulesskiy
Потвърден имейл адрес: helsinki.fi
Заглавие
Позовавания
Позовавания
Година
Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia
T Pemovska, M Kontro, B Yadav, H Edgren, S Eldfors, A Szwajda, ...
Cancer discovery 3 (12), 1416-1429, 2013
452*2013
Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies
B Yadav, T Pemovska, A Szwajda, E Kulesskiy, M Kontro, R Karjalainen, ...
Scientific reports 4 (1), 1-10, 2014
3342014
Heparan sulfate proteoglycan syndecan-3 is a novel receptor for GDNF, neurturin, and artemin
MM Bespalov, YA Sidorova, S Tumova, A Ahonen-Bishopp, ...
Journal of Cell Biology 192 (1), 153-169, 2011
2512011
Methods for high-throughput drug combination screening and synergy scoring
L He, E Kulesskiy, J Saarela, L Turunen, K Wennerberg, T Aittokallio, ...
Cancer systems biology: methods and protocols, 351-398, 2018
2012018
PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells
O Kauko, CM O’Connor, E Kulesskiy, J Sangodkar, A Aakula, S Izadmehr, ...
Science translational medicine 10 (450), eaaq1093, 2018
1532018
N-syndecan deficiency impairs neural migration in brain
A Hienola, S Tumova, E Kulesskiy, H Rauvala
The Journal of cell biology 174 (4), 569-580, 2006
1442006
Expression of the recombinant antibacterial peptide sarcotoxin IA in Escherichia coli cells
VS Skosyrev, EA Kulesskiy, AV Yakhnin, YV Temirov, LM Vinokurov
Protein expression and purification 28 (2), 350-356, 2003
1002003
Antifungal application of nonantifungal drugs
M Stylianou, E Kulesskiy, JP Lopes, M Granlund, K Wennerberg, ...
Antimicrobial agents and chemotherapy 58 (2), 1055-1062, 2014
812014
Intertumoral heterogeneity in patient-specific drug sensitivities in treatment-naïve glioblastoma
E Skaga, E Kulesskiy, A Fayzullin, CJ Sandberg, S Potdar, A Kyttälä, ...
BMC cancer 19, 1-14, 2019
732019
Phosphoproteomics to characterize host response during influenza A virus infection of human macrophages
S Söderholm, DE Kainov, T Öhman, OV Denisova, B Schepens, ...
Molecular & cellular proteomics 15 (10), 3203-3219, 2016
702016
Identification and tracking of antiviral drug combinations
A Ianevski, R Yao, S Biza, E Zusinaite, A Männik, G Kivi, A Planken, ...
Viruses 12 (10), 1178, 2020
642020
Phosphoproteome and drug-response effects mediated by the three protein phosphatase 2A inhibitor proteins CIP2A, SET, and PME-1
O Kauko, SY Imanishi, E Kulesskiy, L Yetukuri, TD Laajala, M Sharma, ...
Journal of Biological Chemistry 295 (13), 4194-4211, 2020
612020
HB-GAM (pleiotrophin) reverses inhibition of neural regeneration by the CNS extracellular matrix
M Paveliev, KK Fenrich, M Kislin, J Kuja-Panula, E Kulesskiy, M Varjosalo, ...
Scientific reports 6 (1), 33916, 2016
602016
Drug-sensitivity screening and genomic characterization of 45 HPV-negative head and neck carcinoma cell lines for novel biomarkers of drug efficacy
T Lepikhova, PR Karhemo, R Louhimo, B Yadav, A Murumägi, ...
Molecular cancer therapeutics 17 (9), 2060-2071, 2018
482018
Antiviral properties of chemical inhibitors of cellular anti-apoptotic Bcl-2 proteins
D Bulanova, A Ianevski, A Bugai, Y Akimov, S Kuivanen, H Paavilainen, ...
Viruses 9 (10), 271, 2017
482017
Transmembrane prostatic acid phosphatase (TMPAP) interacts with snapin and deficient mice develop prostate adenocarcinoma
IB Quintero, AM Herrala, CL Araujo, AE Pulkka, S Hautaniemi, K Ovaska, ...
PloS one 8 (9), e73072, 2013
372013
High NRF2 levels correlate with poor prognosis in colorectal cancer patients and with sensitivity to the kinase inhibitor AT9283 in vitro
L Torrente, G Maan, A Oumkaltoum Rezig, J Quinn, A Jackson, A Grilli, ...
Biomolecules 10 (10), 1365, 2020
352020
Systematic drug sensitivity testing reveals synergistic growth inhibition by dasatinib or mTOR inhibitors with paclitaxel in ovarian granulosa cell tumor cells
UM Haltia, N Andersson, B Yadav, A Färkkilä, E Kulesskiy, M Kankainen, ...
Gynecologic oncology 144 (3), 621-630, 2017
342017
Precision cancer medicine in the acoustic dispensing era: ex vivo primary cell drug sensitivity testing
E Kulesskiy, J Saarela, L Turunen, K Wennerberg
Journal of laboratory automation 21 (1), 27-36, 2016
312016
Feasibility study of using high-throughput drug sensitivity testing to target recurrent glioblastoma stem cells for individualized treatment
E Skaga, E Kulesskiy, M Brynjulvsen, CJ Sandberg, S Potdar, ...
Clinical and translational medicine 8, 1-15, 2019
252019
Системата не може да изпълни операцията сега. Опитайте отново по-късно.
Статии 1–20